Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Other antineoplastic Drugs >  Nivolumab

Nivolumab

Basic information Safety Supplier Related

Nivolumab Basic information

Product Name:
Nivolumab
Synonyms:
  • Nivolumab
  • BMS 936558
  • MDX 1106
  • ONO 4538
  • Opdivo
  • Nivolumab (anti-PD-1)
  • Nivolumab USP/EP/BP
  • Nivolumab 10mg/ml
CAS:
946414-94-4
MW:
0
Mol File:
Mol File
More
Less

Nivolumab Chemical Properties

storage temp. 
Store at -80°C
form 
Liquid
color 
Colorless to light yellow
More
Less

Safety Information

Hazardous Substances Data
946414-94-4(Hazardous Substances Data)
More
Less

Nivolumab Usage And Synthesis

Mechanism of action

Nivolumab is a fully human, monoclonal IgG4 antibody that binds to programmed death-1 (PD-1) receptors with high specificity and affinity. PD-1 is expressed on T cells and dampens their immune response upon binding ligands PD-L1 and PD-L2 on APCs. This mechanism is pivotal to regulating central and peripheral tolerance. In cancer, aberrant PD-L1 expression by tumor cells or immune cells in the tumor microenvironment deactivates PD-1, expressing tumor-infiltrating lymphocytes, thereby allowing tumor cells to escape immune recognition and elimination. By inhibiting PD-1 function, nivolumab releases immune cells from pathological immune suppression, allowing them to recognize and counter tumor cells.

Clinical Use

Monoclonal antibody:
Treatment of advanced (unresectable or metastatic) melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell cancer of the head and neck and urothelial carcinoma

Side effects

The most common Immune-related adverse events (iRAEs) affect systems include the gastrointestinal and integumentary systems, usually manifesting as a pruritic rash, diarrhea, or colitis. When immune-mediated endocrine inflammation subdues, glandular function may be compromised, thus necessitating permanent hormone substitution. This includes nivolumab-induced hypothyroidism, hypopituitarism, adrenal insufficiency, and diabetes mellitus type 1.
Immune-mediated pneumonitis is a rare adverse effect associated with severe manifestations. Immune-related myocarditis is a very uncommon adverse event with high lethality. Less common adverse effects include ocular (uveitis, conjunctivitis, myositis of periocular muscles), inflammatory hepatitis, endocrinopathies such as hypothyroidism, hypopituitarism, and adrenal insufficiency. Other rare adverse events include those affecting the neurological system (encephalitis, Guillain-Barré syndrome).

Drug interactions

Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant use

Metabolism

The metabolic pathway of nivolumab has not been investigated. It is expected to be degraded into small peptides and amino acids via catabolic pathways in the same way as endogenous IgG

References

[1] Anthony V Serritella, Niraj K Shenoy. “Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis.” Jama Oncology (2023): 1441–1446.
[2] Jonathan Ho, C. Kelly, Erick A. Argueta. “S3644 Nivolumab-Induced Liver Injury.” American Journal of Gastroenterology (2021).
[3] Yang Wang. “Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study.” Anti-Cancer Drugs (2024).

NivolumabSupplier

Hefei Hirisun Pharmatech Co., Ltd. Gold
Tel
+86-0551-62678551 +86-15056975894
Email
sales@hirisunpharm.com
Shanghai Minkai Biological Technology Co., Ltd Gold
Tel
021-021-52919136 17315815539
Email
2804155403@qq.com
Hubei wei shi reagent group ltd., company Gold
Tel
027-59102966 18717199209
Email
2853877583@qq.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
Wuhan Sunrise Technology Development Co., Ltd.
Tel
27-027-83314682 13554138826
Email
whsrtech@vip.163.com